NCT05506813 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bordignon A, Devita M, Sergi G, Coin A
"Cerebellar cognitive reserve": a possible further area of investigation. Aging Clin Exp Res. 2021 Oct;33(10):2883-2886. doi: 10.1007/s40520-021-01795-1. Epub 2021 Feb 17.
Bouscary A, Quessada C, René F, Spedding M, Turner BJ, Henriques A, Ngo ST, Loeffler JP
Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Semin Cell Dev Biol. 2021 Apr;112:82-91. doi: 10.1016/j.semcdb.2020.10.008. Epub 2020 Nov 5. Review.
Onder H, Ozyurek O
The impact of distinct cognitive dual-tasks on gait in Parkinson's disease and the associations with the clinical features of Parkinson's disease. Neurol Sci. 2021 Jul;42(7):2775-2783. doi: 10.1007/s10072-020-04874-9. Epub 2020 Nov 4.

Comparative Effects of Cognitive and Motor Dual Task Training on Balance and Quality Of Life in Parkinson's Patients

Clinical trial NCT05506813 - References